Cover Image

Medications for Nausea and Vomiting of Pregnancy and the Risks for Adverse Birth Outcomes

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Laure Sillis, Essi Whaites Heinonen, Michael Ceulemans, Veerle Foulon, Yunjun Luo, Diana Johnson, Christina D. Chambers
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Pharmacoepidemiology and Drug Safety
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Medication, Vaccine, and Folic Acid Use Among Pregnant Women in Belgium: Insights from the BELpREG Cohort
by: Laure Sillis, et al.
Published: (2026)

Letter to the Editor re Davis et al., 2023: BELpREG, the first of its kind real‐world data source on medication use in pregnancy in Belgium
by: Michael Ceulemans, et al.
Published: (2024)

Identification of Chronic Hypertension in Pregnancy in Three Administrative Data Sources Among Medicaid‐Funded Births in California
by: Erin Delker, et al.
Published: (2024)

The Use of Japanese Traditional (Kampo) Medicines Before and During Pregnancy in Japan: The Tohoku Medical Megabank Project Birth and Three‐Generation Cohort Study
by: Aoi Noda, et al.
Published: (2024)

Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review
by: Shahd A. Ageeb, et al.
Published: (2024)

Detecting and Dating Early Non‐live Pregnancy Outcomes: Generation of a Novel Pregnancy Algorithm From Norwegian Linked Health Registries
by: Hedvig Nordeng, et al.
Published: (2024)

Perinatal Outcomes After the Use of Kampo Medicines Containing Ephedra During Pregnancy
by: Aoi Noda, et al.
Published: (2025)

Comparison of Linked EHR ‐Pharmacy Data and Administrative Claims Data: Medication Fills During Pregnancy
by: Gregory P. Jansen, et al.
Published: (2025)

Association of Pharmacist Interventions With Adverse Drug Events and Potential Adverse Drug Events
by: W. N. Kelly, et al.
Published: (2024)

Re‐Exposure to Culprit Medication Following Adverse Drug Event Diagnosis in Canadian Emergency Department Patients: A Cohort Study
by: Maeve E. Wickham, et al.
Published: (2024)

A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
by: Le Hai, et al.
Published: (2024)

Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan
by: Kei Morishita, et al.
Published: (2025)

The Effect of Isoniazid for Tuberculosis Prevention on Pregnancy Risk Among Women Living With HIV on Antiretroviral Treatment and Progestin‐Based Hormonal Contraception
by: Karen Diepstra, et al.
Published: (2025)

Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model
by: Theresa Burkard, et al.
Published: (2024)

Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
by: Zhenpo Zhang, et al.
Published: (2025)

Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark
by: Theis Skovsgaard Itenov, et al.
Published: (2025)

Comment on “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan” by Morishita K. Et Al.
by: Mesut Gungor, et al.
Published: (2025)

Evaluating an ICD‐10 Based Proxy for Date of Birth in Electronic Health Record Data
by: Sara Burns, et al.
Published: (2025)

The Antiretroviral Pregnancy Registry: Three decades of prospective monitoring for birth defects
by: Jessica D. Albano, et al.
Published: (2024)

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
by: Sandrine Colas, et al.
Published: (2024)

Severe Cutaneous Adverse Reactions in Hospitalized Children: A Pilot Validation Study
by: Bahar Javdan, et al.
Published: (2024)

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
by: Jiayu Yuan, et al.
Published: (2024)

A Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental Outcomes
by: Sandra Lopez‐Leon, et al.
Published: (2025)

Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib
by: Connor Frey
Published: (2025)

The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids: A Questionnaire Survey in Denmark
by: Dana Backran, et al.
Published: (2024)

Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims Database
by: Sarah R. Hoffman, et al.
Published: (2024)

Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic review
by: Xue‐Feng Jiao, et al.
Published: (2024)

Risk of Major Congenital Malformations Associated With First‐Trimester Exposure to Topical Antifungal Medications: A Large Claims Database Study
by: Tadaharu Kunitoki, et al.
Published: (2025)

Quality of Clinical Information in Pregnancy Pharmacovigilance Data Sources—A Contribution of the ConcePTION Project
by: Yrea R. J. van Rijt‐Weetink, et al.
Published: (2025)

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals
by: Priscilla O. M. V. Lopes, et al.
Published: (2026)

A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
by: Le Hai, et al.
Published: (2025)

Ultrasound Procedure Codes Enable Timely Surveillance of Ongoing Pregnancies: A Nationwide Population‐Based Register Study
by: Margrethe Greve‐Isdahl, et al.
Published: (2026)

The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance
by: Kaleen N. Hayes, et al.
Published: (2025)

Validation of Immune‐Related Adverse Event (irAE) Case Definitions in a Real‐World Lung Cancer Population
by: James S. Heyward, et al.
Published: (2025)

Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study
by: Y. Shi, et al.
Published: (2025)

Aioli: Standardising Drugs in the FDA Adverse Event Reporting System ( FAERS ) to RxNorm and Anatomical Therapeutic Chemical ( ATC ) Codes
by: Rowan E. Parry, et al.
Published: (2025)

Knowledge, Attitudes and Sources of Information About Adverse Drug Reactions—A Survey Study Among Patients and Healthcare Professionals in Poland
by: Magdalena Niedzielko, et al.
Published: (2026)

Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008–2022)
by: Isatu Jalloh, et al.
Published: (2026)

Valproic Acid‐Induced Congenital Disorders, an Analysis in EudraVigilance and a Literature Review of Valproic Acid Utilization During Pregnancy
by: Mădălina Hurubă, et al.
Published: (2025)

Longitudinal Trends in Non‐Insulin Pharmacotherapy for Type 2 Diabetes in Australian Women of Reproductive Age: Implications for Planned and Unplanned Pregnancies
by: Farah Hashmani, et al.
Published: (2026)